Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Open access
Van Cutsem, Eric, Eng, Cathy, Nowara, Elzbieta, Świeboda-Sadlej, Anna, Tebbutt, Niall C., Mitchell, Edith, Davidenko, Irina, Stephenson, Joe, Elez, Elena, Prenen, Hans, Deng, Hongjie, Tang, Rui, McCaffery, Ian, Oliner, Kelly S., Chen, Lisa, Gansert, Jennifer, Loh, Elwyn, Smethurst, Dominic, Tabernero, Josep · 2014 · Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody (mAb), has demonstrated efficacy in patients with wild-type KRAS metastatic colorectal cancer (mCRC). Rilotumumab and ganitumab are investigational, fully human mAbs against hepatocyte growth factor (HGF)/scatter factor and IGF1R, respectively. Here we evaluate combining rilotumumab or ganitumab with panitumumab in previously treated patients with wild-type KRAS mCRC. Experimental Design: Part 1 was a phase Ib dose-finding study of panitumumab plus rilotumumab. The primary endpoint was the incidence of dose-limiting toxicities (DLT). Part 2 was a randomized phase II trial of panitumumab in combination with rilotumumab, ganitumab, or placebo. The primary endpoint was objective response rate (ORR); safety, progression-free survival (PFS), and overall survival (OS) were secondary endpoints. Archival tissue specimens were collected for exploratory correlative work. Results: In part 1, no DLTs were reported. A recommended phase II dose of 10 mg/kg rilotumumab was selected. In part 2, for the panitumumab plus rilotumumab (n = 48), panitumumab plus ganitumab (n = 46), and panitumumab plus placebo arms (n = 48), the ORRs were 31%, 22%, and 21%, respectively. The median PFS was 5.2, 5.3, and 3.7 months and median OS 13.8, 10.6, and 11.6 months, respectively. Adverse events were tolerable. Exploratory biomarker analyses, including MET and IGF-related protein expression, failed to indicate conclusive predictive evidence on efficacy endpoints. Conclusions: Panitumumab plus rilotumumab met the prespecified criterion for improvement in ORR whereas ganitumab did not. This is the first study to suggest a benefit for combining an HGF inhibitor (rilotumumab) with panitumumab in previously treated patients with wild-type KRAS mCRC. Clin Cancer Res; 20(16); 4240–50. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-2752

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 116

Metadata

Authors
Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., Deng, H., Tang, R., McCaffery, I., Oliner, K. S., Chen, L., Gansert, J., Loh, E., Smethurst, D., & Tabernero, J.
Affiliations
  • 1University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium;
  • The University of Texas MD Anderson Cancer Center (US)
  • 7Instytut im. M. Sklodowskiej-Curie, Gliwice;
  • Medical University of Warsaw (PL)
  • Austin Health (AU)
  • Thomas Jefferson University (US)
  • 10Krasnodar City Oncology Center, Krasnodar, Russia;
  • 4Cancer Centers of the Carolinas, Greenville, South Carolina;
  • 11Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain; and
  • KU Leuven (BE)
  • Amgen (United States) (US)
  • Amgen (United Kingdom) (GB)
  • Universitat Autònoma de Barcelona (ES)
Venue
Clinical Cancer Research
Published
2014-08-13
Volume
20
Issue
16
Pages
4240-4250
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1987270095
Cited by
110
References
29
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 9 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 7 · 2018: 10 · 2017: 17 · 2016: 12 · 2015: 23 · 2014: 3
FWCI
8.86
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Amgen
  • National Cancer Institute (P01CA130821, P30CA016672, P30CA056036)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
panitumumab, rilotumumab, ganitumab, KRAS wild-type, metastatic colorectal cancer, anti-EGFR monoclonal antibody, IGF1R inhibitors, combination therapy, dose-limiting toxicity, objective response rate, progression-free survival, overall survival, predictive biomarkers, MET expression
MeSH terms
Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Follow-Up Studies, Humans, Liver Neoplasms, Male, Middle Aged, Mutation, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Proto-Oncogene Proteins, Colorectal Neoplasms, Survival Rate, Proto-Oncogene Proteins p21(ras), ras Proteins, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2752
The paper
Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., Deng, H., Tang, R., McCaffery, I., Oliner, K. S., Chen, L., Gansert, J., Loh, E., Smethurst, D., & Tabernero, J. (2014). Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2752

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.